ArticleAnnals of hematology2026
LRP6 aggravates proliferation, invasion, and immunosuppression in diffuse large B-cell lymphoma: a novel prognostic marker and therapy target.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Low-density lipoprotein receptor (LDLR)-related protein 6 (LRP6) has been found to be highly expressed in various solid tumors, correlating with malignant phenotypes and poor prognosis. However, the role of LRP6 in diffuse large B cell lymphoma (DLBCL) remains unclear. In this study, we revealed that LRP6 expression was significantly elevated in DLBCL patients. High expression of LRP6 is not only associated with tumor subtype, Ann Arbor stage, and extra-nodal invasion, but also with poor prognosis. The knockout of LRP6 significantly inhibited cell proliferation and migration, induced cell cycle arrest, and promoted apoptosis in DLBCL cells. Mechanistically, LRP6 knockout inhibited both the Wnt/β-catenin and mTORC1 signaling pathways. Furthermore, we found that LRP6 knockout reduced the expression of indoleamine 2,3-dioxygenase 1 (IDO1), a negative regulator within the tumor microenvironment (TME), and consequently decreased the level of kynurenine (KYN), indicating a reduction in IDO1 enzymatic activity. Additionally, LRP6 knockout suppressed DLBCL xenograft tumor growth. Collectively, our findings suggested that high LRP6 expression in DLBCL patients was associated with poor prognosis, and LRP6 contributes to DLBCL progression and immunosuppression. Taken together, these findings highlight LRP6 as a potential novel prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.